Latest News by Industry
NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $151.8 million in its fourth quarter.
The Novato, California-based company said it had a loss of $2.16 per share.
The results missed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $2.03 per share.
The biotechnology company posted revenue of $103.3 million in the period, surpassing Street forecasts. Nine analysts surveyed by Zacks expected $103.1 million.
For the year, the company reported a loss of $707.4 million, or $10.12 per share. Revenue was reported as $363.3 million.
Ultragenyx expects full-year revenue in the range of $425 million to $450 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a RARE">Zacks stock report on RARE at https://www.zacks.com/ap/RARE